UPDATED FEB 2013 ELTP Due Diligence Investor Info

New Post Public Reply Private Reply Replies (0) Message Board

Feb 5, 2013 at 9:38 AM

UPDATED FEB 2013 ELTP Due Diligence Investor Info

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has five commercial products with five additional products under review, pending approval by the FDA.

Elite’s lead pipeline products include abuse resistant opioids utilizing the Company’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Elite also has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories.

Elite operates a FDA GMP(Good Manufacturing Practices) and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

Link to 11 Billion dollar NYSE company - ACT- Actavis Labs distributing ELTP’s Phendimetrazine

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=84198

Link to product pipeline:

http://www.elitepharma.com/product_pipeline.asp

Link to SEC filings:

http://investing.money.msn.com/investments/se...ymbol=ELTP

Recent PR's:

http://www.elitepharma.com/investor_relations.asp

12/13/2012 ELITE PHARMACEUTICALS, INC. ANNOUNCES AGREEMENT FOR SUPPLY OF PHENTERMINE ACTIVE INGREDIENT

11/14/2012 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal 2013
...Revenues from new products continue to grow

PATENTS:

Since our incorporation, we have secured eight United States patents of which two have been assigned for a fee to Celgene Corporation for pulsed delivery of methylphenidate. Elite’s patents are:
PATENTS
U.S. patent 5,871,776
U.S. patent 5,902,632
U.S. patent 5,837,284 (assigned to Celgene Corporation)
U.S. patent 6,620,439
U.S. patent 6,635,284 (assigned to Celgene Corporation)
U.S. patent 6,926,909
U.S. patent 6,984,402
U.S. patent 8,182,836
We also have pending applications for four additional U.S. patents and four foreign patents. The pending patent applications are for an opioid agonist and antagonist products that Elite is developing to be used with controlled-release Oxycodone and other opioids to minimize the abuse potential for the opioids.

CEO Funding

Ceo Jerry Treppel personally invested 1 million dollars of his own money in 2 $500,000 non-dilutive financings to keep the research and products sales increases on target.

Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that it has amended the bridge loan agreement ("Loan Agreement") with Jerry Treppel, Elite's Chairman & CEO. Pursuant to the amendment to the Loan Agreement, Mr. Treppel has agreed to increase the maximum principal amount of the line of credit from $500,000 to $1,000,000. All other terms remain the same. The additional proceeds will be used primarily for working capital to support Elite's increase in production and growth of sales.
A copy of the amendment to the Loan Agreement will be filed in a Current Report on Form 8-K which will be filed with the Securities and Exchange Commission.

http://ih.advfn.com/p.php?pid=nmona&article=55384279

Outstanding shares :

As of November 8, 2012 the issuer had outstanding 350,337,260 shares of common stock

Transfer Agent:

American Stock Transfer & Trust Company, LLC.
6201 15th Avenue
Brooklyn, NY 11219

Phone: 800-937-5449
Fax: 718-236-2641
E Mail: info@amstock.com

Investor Relations Contact:

Dianne Will
(201) 367-7889
E Mail: dianne@elitepharma.com

http://www.elitepharma.com/ir_contact_us.asp

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tripadvisor Faces Investigation Over Securities Violations

Tripadvisor's Stock Dive: Investor Panic or Opportunity? Woah, if you had a stake in Tripadvisor (NASDAQ: TRIP) recently, you know it hasn't been a walk in the park. Shares took a nosedive of over 20% on November 5, 2026, after they unveiled a frightening $313.1 million net loss for the third quarter. What stirred the pot, you ask? Well, toss in a goodwill impairment...

Cavli's Latest Innovations Shine at electronica 2026

Cavli Wireless: Paving the Path for Smarter IoT There's a storm brewing in Munich at electronica 2026, and Cavli Wireless is the name spurred across tech-savvy lips. With their latest revelation—the P16QS LTE Cat 1bis module and Cortex AI—the firm’s tossing bold challenges at the IoT and AI landscape. It's a gutsy move, cementing their role as a frontier pusher in a...

NativeSeed Group Expands with Sharp Brothers Buyout

A Quiet Giant Grows Stronger Who would've thought? While most folks are caught up watching tech stocks or energy commodities spike, NativeSeed Group just made a move worth raising an eyebrow over. On November 5, 2026, they scooped up the assets of Sharp Brothers Seed Company, a small firm in Healy, Kansas known for top-tier native seed cleaning. We've got ourselves a...

James Scott Farrin Secures 12th 'Best Law Firms' Honor

Durham's Pride in Legal Excellence Just like ol' reliable clockwork, James Scott Farrin has clinched another honor that makes the legal landscape take note. This Durham-based law office, a heavyweight in the injury claims scene, isn't just shuffling papers; they're racking up accolades on the list of 'Best Law Firms' for the 12th year running. Now, that's no small feat....

Curis Prepares for Q3 2026 Results Amid Tough Sector Trends

All Eyes on Curis as Q3 Financials Loom Just when you think you’ve seen it all in this wild biotech ride, Curis, Inc. (NASDAQ: CRIS) is prepping to roll out their third quarter financial and operating results. Circle your calendars for November 12, 2026, because the clock’s ticking down to their 4:00 p.m. ET announcement, swiftly followed by a conference call at 4:30...

Bioactive Research: Converting Science into Guidance

Unlocking the Science of Dietary Bioactives Amidst a world swimming in kale smoothies and exotic teas, ILSI U.S. & Canada gathered the sharpest minds to discuss dietary bioactives, an area once shrugged off but now coming into its own. On October 28, 2026, over 250 folks from government, academia, and industry tuned in, looking to understand how these compounds, found in...

3D Systems Faces Scrutiny Over Earnings Report

3D Systems' Earnings Leave Investors on Edge Like a hot potato, 3D Systems’ latest earnings report has investors feeling jittery. And with good reason–their third-quarter numbers are a mixed bag as they somehow squeezed out a positive $3.1 million in adjusted EBITDA and yet posted a yawning $33.5 million GAAP net loss. No wonder heads are spinning over at SueWallSt,...

Breeze Airways Secures $228M for Fleet Expansion

Breeze Airways and AIP's Milestone Deal Just as the ink is drying on the balance sheets, Breeze Airways is busy making significant moves in the aviation game. Partnering with AIP Capital, they just locked in a $228 million secured debt facility to grab six new Airbus A220-300 aircraft. Now, that’s how you stake your claim in the market. What we’ve got here isn’t...

Golf Cart Market Set to Surge as Electric Mobility Rises

Revving Up the Golf Cart Market The golf cart market's looking like it's gearing up for one heck of a drive. Mordor Intelligence just dropped a report claiming we're gonna see the market haul itself from USD 2.44 billion in 2026 to USD 3.24 billion by 2031. That’s a tidy little jump with a CAGR of 5.81%. Blame it on electric mobility's allure, spruced-up lithium battery...

Chris Auffenberg Delivers Ford Blue Advantage Gains

Can't Ignore Ford's New Strategy in Pre-Owned Cars The auto industry may feel like a runaway train sometimes, and keeping up with the latest turns can be a headache. But here's something catching my eye: Chris Auffenberg Ford's new move with the Ford Blue Advantage certified pre-owned vehicles. It's not just any run-of-the-mill used car deal—this one's got some beef...